Recombinant Human Erythropoietin in Children with Solid Tumors and Chemotherapy-induced Anemia
Journal Title: Iranian Journal of Blood and Cancer - Year 2018, Vol 10, Issue 1
Abstract
Background: In patients undergoing chemotherapy for cancer, anemia is part of the progression of the disease. Considering the effects of anemia on quality of life of the patients, the prevention and treatment of chemotherapy-induced anemia is crucial. This study was aimed to evaluate the efficacy of recombinant human erythropoietin in reducing the need for blood transfusion in children with solid tumors receiving chemotherapy. Methods: In a clinical trial, 57 children referred to the pediatric centre of Tabriz University of Medical Sciences with a diagnosis of solid tumor were randomly assigned into two groups. The intervention group (n=29) received recombinant human erythropoietin (rHuEPO) at a dose of 450 IU/kg subcutaneously once a week for 12 weeks, and the control group (n=28) received no intervention in this regard. Hemoglobin levels were analysed at the beginning and end of the study. The need for blood transfusion was also assessed in the patients. Results: The mean Hb at the beginning of the study was 8.85±1.01 and 8.98±0.11 g in the intervention and control groups, respectively. The mean Hb at the end of the study was 9.78±0.32 g/dl in the intervention group and 7.79±0.24 g/dl in the control group. Hb level was significantly higher in the intervention group at the end of the 12 weeks of treatment with rHuEPO than in the control group (P=0.001). Conclusion: Based on the results of this study, rHuEPO administration seems to be beneficial in the prevention and treatment of chemotherapy-induced anemia in children with solid tumors and reduces the amount of blood transfusion in these patients.
Authors and Affiliations
Amir Ataollah Hiradfar, Azim Rezamand, Matin Pourghasem, Sepideh Karkon Shayan, Behnaz Ghamari, Farid Karkon Shayan
Keywords
Related Articles
- EP ID EP358584
- DOI -
- Views 70
- Downloads 0
Range Determination of Antigen Expression in Myeloid, Erythroid and Lymphoid Cell Lineages among Patients with Myelodysplastic Syndrome
Background: Myelodysplastic syndrome is a mixed clonal disorder of bone marrow progenitor cells. Understanding the pattern of the different lineage-specific, immature, and mature markers in myelodysplastic syndrome will...
Evaluation of Anthracycline Effects on NT-ProBNP Plasma Level in Children with Malignancy
Background: NT-proBNP is a marker that is released from ventricles in response to pressure and volume overload. Raised plasma level of NT-proBNP is seen in ventricular dysfunction, ventricular muscular mass reduction or...
Investigation of Leptin, Leukemia Inhibitory Factor (LIF), and IL-6 Serum Levels in Myeloid Leukemia
Background: Leptin has been implicated in the differentiation and proliferation of hematopoietic cells. Leukemia inhibitory factor (LIF) may play an important role, along with Interleukin-6 (IL-6) and granulocyte colony...
Molecular Markers in Neuroblastoma
Neuroblastoma, one of the common malignant childhood tumors, arises from neuroblast cells derived from the neural crest and destined for the adrenal medulla and the sympathetic nervous system and shows remar...
Patients Perspective in Plasma Products (Focus on Hemophilia)
Effective treatment of inherited bleeding disorders has become available from plasma in the last 50 years. Plasma-derived medicinal products are used in Iran in a wide variety of clinical problems. Some of these...